Prognostic factors influencing the patency of hemodialysis vascular access: Literature review and novel therapeutic modality by far infrared therapy

Journal of the Chinese Medical Association

Volumn 72, Issue 3, 2009, Pages 109-116

  Lin, Chih Ching ^a,b   Yang, Wu Chang ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Far infrared therapy; Genotype polymorphism; Heme oxygenase 1; Hemodialysis; Vascular access

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM PHOSPHATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEME OXYGENASE 1; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN A; PHOSPHOLIPID ANTIBODY; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; WARFARIN;

ARTERIOVENOUS FISTULA; CARDIOVASCULAR DISEASE; CELL DAMAGE; CLINICAL COMPETENCE; CLINICAL EFFECTIVENESS; DINUCLEOTIDE REPEAT; DNA POLYMORPHISM; DRUG EFFICACY; ENDOTHELIUM CELL; EXERCISE; FAR INFRARED THERAPY; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; HYPERTHERMIC THERAPY; HYPOALBUMINEMIA; HYPOTENSION; LITERATURE; OXIDATIVE STRESS; PATIENT REFERRAL; POSTOPERATIVE INFECTION; POSTOPERATIVE THROMBOSIS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SHEAR STRESS; SURGICAL TECHNIQUE; SURVIVAL; THROMBOCYTE ACTIVATION; UPREGULATION; VASCULAR ACCESS; VASCULAR ENDOTHELIUM; VENOUS STASIS;

EID: 65249184455     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70035-8     Document Type: Review

References (73)

1. Roy-Chaudhury P, Sukhatme VP, Cheung AK Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nepbrol 2006;17:1112-27.
2. Schwab SJ, Harrington JT, Singh A, Roher F, Shohaib SA, Perrone RD, Meyer Y, et al. Vascular access for hemodialysis. Kidney Int 1999;55:2078-90.
3. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nepbrol 1996;7:523-35.
4. Paun M, Beach K, Ahmad S, Hickman R, Meissner M, Plett C, Strandness DE Jr, et al. New ultrasound approaches to dialysis access monitoring. Am J Kidney Dis 2000;35:477-81.
5. Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis 1993-21:457-71.
6. Lin CC, Chang CF, Chiou HJ, Sun YC, Chiang SS, Lin MW, Lee PC, et al. Variable pump flow-based Doppler ultrasound method: a novel approach to the measurement of access flow in hemodialysis patients. J Am Soc Nepbrol 2005;16: 229-36.
7. Abularrage CJ, Sidawy AN, Weiswasser JM, White PW, Arora S. Medical factors affecting patency of arteriovenous access. Semin Vase Surg 2004;17:25-31.
8. Barth C, Boer W, Garzoni D, Kuenzi T, Ries W, Schaefer P, Schneditz D, et al. Characteristics of hypotension-prone haemodialysis patients: is there a critical relative blood volume? Nephrol Dial Transplant 2003;18:1353-60.
9. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000;36:68-74.
10. Haviv YS. Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: cause or effect? Nephron 2000;86:447-54.
11. Brunet P, Aillaud MF, San Marco M, Phihp-Joet C, Dussol B, Bernard D, Juhan-Vague I, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995;48:794-800.
12. Prakash I, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995;126:347-52.
13. McCully KS. Homocysteine and vascular disease. Nat Med 1996;12:386-9.
14. Rajkumar V, Ragatzki P, Sima A, Levy J. Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infarctions: implications for therapy. Endocrine 1999;11:57-60.
15. Fukasawa M, Matsushita K, Kamiyama M, Mikami Y, Araki I, Yamagata Z, Takeda. M. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 2003; 41:637-42.
16. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 1999;55:315-20.
17. Hojs R, Gorenjak M, Ekart R, Dvorsak B, Pecovnik-Balon B. Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail 2002-124:215-22.
18. Shemin D, Lapane YL, Bausserman L, Kanaan E, Kahn S, Dworkin L, Bostorn AG. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 1999;110:1095-9.
19. Carmody BJ, Arora S, Avena R, Cosby K, Sidawy AN. Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells. J Vasc Surg 1999;30:1121-8.
20. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 2000;102:871-5.
21. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49:147-52.
22. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, Enzenberger B, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000-111:1106-16.
23. Sampram ES, Lindblad B. The impact of factor V mutation on the risk for occlusion in patients undergoing peripheral vascular reconstructions. Eur J Vasc Endovasc Surg 2001;22:134-8.
24. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994;271: 999-1003.
25. Cressman MD, Heyka RJ, Paganim EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475-82.
26. Kim YO, Song HC, Yoon SA, Yang CW, Kra NI, Choi YJ, Lee EJ, et al. Preexisting intimal hyperplasia of radial artery is associated with early failure of radiocephalic arteriovenous fistula in hemodialysis patients. Am J Kidney Dis 2003;41:422-8.
27. Mattana J, Effiong C, Kapasi A, Singhal PC. Leukocyte-polytetrafluoroethylene interaction enhances proliferation of vascular smooth muscle cells via tumor necrosis factor-alpha secretion. Kidney Int 1997;52:1478-85.
28. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis 2001;37:970-80.
29. Olsson LF, Odselius R, Ribbe E, Hegbrant J. Evidence of calcium phosphate depositions in stenotic arteriovenous fistulas. Am J Kidney Dis 2001;38:377-83.
30. Chuang YC, Chen JB, Yang LC, Kuo CY. Significance of platelet activation in vascular access survival of haemodialysis patients. Nephrol Dial Transplant 2003;18:947-54.
31. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2002;40:1255-63.
32. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994;45:1477-83.
33. Huang P, Hawthorne WJ, Peng A, Angeli GL, Medbury HJ, Fletcher JP. Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model. Am J Surg 2001;181:492-8.
34. Association between recombinant human erythropoictin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990; 300:573-8.
35. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nepbrol 1994; 4:1809-13.
36. Leaf DA, MacRae HS, Grant E, Kraut J. Isometric exercise increases the size of forearm veins in patients with chronic renal failure. Am J Med Sci 2003;325:115-9.
37. Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, Owen W Jr. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol 2002;55:711-6.
38. Chesser AM, Baker LR. Temporary vascular access for first dialysis is common, undesirable and usually avoidable. Clin Nephrol 1999;51:228-32.
39. Saeed Abdulrahman I, Al-Mueilo SH, Bokhary HA, Ladipo GO, Al-Rubaish A. A prospective study of hemodialysis access-related bacterial infections. J Infect Chemother 2002;8:242-6.
40. Hodges TC, Fillinger MF, Zwolak RM, Walsh DB, Bech F, Cronenwett JL. Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg 1997;26:1009-19.
41. Heine GH, Ulrich C, Sester U, Sestcr M, Kohler H, Girndt M. Transforming growth factor betal genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int 2003;64:1101-7.
42. Maines MD. The hcme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997;37: 517-54.
43. Maines MD, Trakshel GM, Kutty RK. Characterization of two constitutive forms of rat liver microsomal heme oxygenase: only one molecular species of the enzyme is inducible. J Biol Chem 1986;261:411-9.
44. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988;2:2557-68.
45. McCoubrey WK Jr, Huang TJ, Maines; MD. Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem 1997-1247: 725-32.
46. Durante W. Heme oxygenase- 1 in growth control and its clinical application to vascular disease. J Cell Physiol 2003;195:373-82.
47. Deramaudt BM, Braunstein S, Remy P, Abraham NG. Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J Cell Biochem 1998; 68:121-7.
48. Liu XM, Chapman GB, Peyton KJ, Schafer Al, Durante W. Carbon monoxide inhibits apoptosis in vascular smooth muscle cells. Cardiovasc Res 2002;55:396-405.
49. Silva RF, Rodrigues CM, Brites D. Bilirubin-induced apoptosis in cultured rat neural cells is aggravated by chenodeoxycholic acid but prevented by ursodeoxycholic acid. J Hepatol 2001; 34:402-8.
50. Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc NatlAcad Sci USA 1994; 91:5987-91.
51. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000;66:187-95.
52. Exner M, Schillinger M, Minar E, Mlekusch W, Schlerka G, Haumer M, Marmhalter C, et al. Herne oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutancous transluminal angioplasty. J Endovasc Ther 2001;8:433-40.
53. Schillinger M, Exner M, Mlekusch W, Ahmadi I, Rumpold H, Mannhalter C, Wagner O, et al. Heme oxygenase-1 genotype is a vascular anti-inflammatory factor following balloon angioplasty. J Endovasc Ther 2002;9:385-94.
54. Chen YH, Lin SJ, Lin MW, Tsai HL, Kuo SS, Chen JW, Charng MJ, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002;111:1-8.
55. Kaneda H, Ohno M, Taguchi J, Togo M, Hashimoto H, Ogasawara K, Aizawa T, et al. Herne oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002;22:1680-5.
56. Schillinger M, Exner M, Mlekusch W, Domanovits H, Huber K, Mannhalter C, Wagner O, et al. Herne oxygenase- 1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb Res 2002;106:131-6.
57. Lin CC, Yang WC, Lin SJ, Chen TW, Lee WS, Chang CF, Lee PC, et al. Length polymorphism in heme oxygenase- 1 is associated with artcriovenous fistula patency in hemodialysis patients. Kidney Int 2006;69:165-72.
58. Toyokawa H, Matsui Y, Uhara J, Tsuchiya H, Teshima S, Nakanishi H, Kwon AH, et al. Promotive effects of far-infrared ray on full-thickness skin wound healing in rats. Exp Biol Med (Maywood) 2003;228:724-9.
59. Capon A, Mordon S. Can thermal lasers promote skin wound healing? Am J Clin Dermatol 2003;4:1-12.
60. Lloyd BJ, Farkas BE, Keener KM. Characterization of radiant emitters used in food processing. J Microw Power Electromagn Energy 2003;38:213-24.
61. Honda K, Inoue S. Sleep-enhancing effects of far-infrared radiation in rats. Int J Biometeorol 1988;32:92-4.
62. Udagawa Y, Nagasawa H. Effects of far-infrared ray on reproduction, growth, behaviour and some physiological parameters in mice. In Vivo 2000;14:321-6.
63. Yu SY, Chiu JH, Yang SD, Hsu YC, Lui WY, Wu CW Biological effect of far-infrared therapy on increasing skin microcirculation in rats. Photodermatol Photoimmunol Photomed 2006;22:78-86.
64. Akasaki Y, Miyata M, Eto H, Shirasawa T, Hamada N, Ikeda Y, Biro S, et al. Repeated thermal therapy up-regulates endothelial nitric oxide synthase and augments angiogenesis in a mouse model of hindlimb ischemia. Circ J 2006;70:463-70.
65. Imamura M, Biro S, Kihara T, Yoshifiku S, Takasaki K, Otsuji Y, Minagoe S, et al. Repeated thermal therapy improves impaired vascular enclothelial function in patients with coronary risk factors. J Am Coll Cardiol 2001;38:1083-8.
66. Ikeda Y, Biro S, Kamogawa V, Yoshifuku S, Eto H, Orihara K, Yu B, et al. Repeated sauna therapy increases arterial endothelial nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. Circ J 2005;69:722-9.
67. Khara T, Biro S, Ikeda Y, Yoshifuku S, Takasaki K, Otsuji Y, Minagoe S, et al. Effects of repeated sauna treatment on ventricular arrhythmias in patients with chronic heart failure. Circ J 2004;68:1146-51.
68. Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. J Am Soc Nephrol 2007;18:985-92.
69. Harrel M, Hoffmann G, Wente MN, Martignoni ME, Buchler MW, Friess H. Randomized clinical trial of the influence of ocal water-filtered infrared A irradiation on wound healing after abdominal surgery. Br J Surg 2006;93:952-60.
70. Lin CC, Liu XM, Peyton K, Wang H, Yang WC, Lin SJ, Durantc W. Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. Arterioscler Thromb Vasc Biol 2008;28:739-45.
71. Kipshidze N, Nikolaychik V, Muckerheidi M, Keelan MH, Chekanov V, Maternowski M, Chawla P, et al. Effect of short pulsed nonablative infrared laser irradiation on vascular cells in vitro and neointimal hyperplasia in a rabbit balloon injury model. Circulation 2001;104:1850-5.
72. Masuda A, Miyata M, Kihara T, Minagoe S, Tei C. Repeated sauna therapy reduces urinary 8-cpi-prostaglandin F(2alpha). Jpn Heart J 2004;45:297-303.
73. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997;17:2309-15.